Global drug eluting balloon market is estimated to be valued at USD 776.8 Mn in 2025, and is expected to exhibit a CAGR of 8.8% during the forecast period (2025-2032). Drug eluting balloons offer an effective alternative to drug eluting stents for treating coronary artery disease by preventing the narrowing of arteries post angioplasty. These work by delivering anti-proliferative drugs like paclitaxel directly to the blood vessel walls through microscopic pores in the balloon catheter. This inhibit excessive neointimal hyperplasia and reduces the risk of restenosis. Growing geriatric population suffering from cardiovascular diseases, increasing incidences of diabetes leading to peripheral artery disease, technological advancements in drug delivery balloon catheters, and rising adoption of minimally invasive procedures can boost demand for drug eluting balloons in the near future.
Market Dynamics:
Global drug eluting balloon market growth is driven by rising prevalence of cardiovascular diseases requiring angioplasty treatments. According to the World Health Organization, cardiovascular diseases are the leading cause of death globally, responsible for over 17 million deaths annually. Moreover, growing elderly population that is more susceptible to arterial diseases boosts demand for drug eluting balloons. However, high costs associated with drug eluting balloons compared to plain old balloons and drug eluting stents limit their adoption in price sensitive markets. Ongoing research and development activities to develop novel drug delivery systems, biodegradable polymers, and formulate combination products offers lucrative opportunities for market players.
Key Features of the Study:
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook